(Q37538535)

20 August 2017

title

Understanding melanoma signaling networks as the basis for molecular targeted therapy (English)

1 reference

20 August 2017

1

Keiran S M Smalley

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Journal of Investigative Dermatology

20 August 2017

published in

1 reference

20 August 2017

volume

130

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

28-37

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Network biology: understanding the cell's functional organization

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Notch1 is an effector of Akt and hypoxia in melanoma development

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

High levels of MMP-1 expression in the absence of the 2G single nucleotide polymorphism is mediated by p38 and ERK1/2 mitogen-activated protein kinases in VMM5 melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

PKB binding proteins. Getting in on the Akt.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

A novel AKT3 mutation in melanoma tumours and cell lines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Guilty as charged: B-RAF is a human oncogene

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Genetics of melanoma predisposition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Major response to imatinib mesylate in KIT-mutated melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Lethality and centrality in protein networks

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Regulation of both apoptosis and cell survival by the v-Src oncoprotein.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

mTOR is activated in the majority of malignant melanomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Raf-1 activates MAP kinase-kinase

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Modeling genomic diversity and tumor dependency in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

BRAFE600-associated senescence-like cell cycle arrest of human naevi

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

A novel transforming gene in a human malignant melanoma cell line

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Activation of N-ras in a human melanoma cell line

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

High frequency of BRAF mutations in nevi

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Stress and mTORture signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Functional and therapeutic significance of Akt deregulation in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Oncogenic shock: turning an activated kinase against the tumor cell.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Cancer: crime and punishment.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

G1 phase progression: cycling on cue

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Apoptosis and melanoma chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Deregulated Akt3 activity promotes development of malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.177

7 January 2021

Identifiers

DOI

10.1038/JID.2009.177

1 reference

Dimensions Publication ID

20 August 2017

1032697678

0 references

1 reference